Opdivo is projected to lead the growth in renal cell carcinoma (RCC) market and be a market leader by 2023, according to a report by GlobalData.
Titled ‘PharmaPoint: Renal Cell Carcinoma – Global Drug Forecast and Market Analysis to 2023‘, the report details how the data obtained from recently conducted trials have strengthened Opdivo’s position as an efficient drug for the treatment of metastatic renal cell carcinoma (mRCC).
The promising outlook for the drug is backed by encouraging survival outcome rates and objective response rates.
The drug is expected to have a high-patient uptake and consequently transform the RCC market, which is currently dominated by tyrosine kinase inhibitors and mTOR inhibitors.
A recent finding regarding Bristol-Myers Squibb’s Opdivo was presented at the American Society of Clinical Oncology conference held in May this year. The findings have labelled the drug as a new standard of care for mRCC.
The GlobalData report forecasts that the RCC market will expand to $3.6bn by 2023 from $2.1bn in 2013 mainly driven by the success of Opdivo. The recent trials measured the efficacy of Opdivo over its competitor Afinitor and have indicated a comparatively better tumour response with Opdivo, which is a positive finding as tumour response is correlated with patient survival.
The results of Phase I and II trials indicate that the survival of patients treated with the drug is promising in the long-term.
Dan Roberts, Ph.D., GlobalData’s senior analyst covering oncology and hematology, says: "These long-term results support the initial data published in the New England Journal of Medicine in September 2015, and further demonstrate that Opdivo significantly improves survival with a good quality-of-life."